DHODH and acute myeloid leukemia: So far, two newly patented human DHODH inhibitors are currently being investigated for AML treatment: ASLAN003, currently being evaluated in Phase II clinical trial (clinical trial identifier: NCT03451084); BAY2402234, a compound by Bayer entered Phase I clinical trials in January 2018 (clinical trial identifier: NCT03404726) [60].